General form of registration statement for all companies including face-amount certificate companies

Consolidated Statement of Operations

v2.4.0.8
Consolidated Statement of Operations (USD $)
3 Months Ended 12 Months Ended
Mar. 31, 2014
Mar. 31, 2013
Dec. 31, 2013
Dec. 31, 2012
Revenue:        
Medical devices $ 526,753 $ 332,919 $ 1,611,709 $ 566,222
Engineering services 534,958 363,330 1,690,235 2,140,355
Total revenue 1,061,711 696,249 3,301,944 2,706,577
Cost of revenue:        
Cost of medical devices 330,125 232,563 1,460,692 553,429
Cost of engineering services 252,103 347,214 1,253,942 1,782,848
Total cost of revenue 582,228 579,777 2,714,634 2,336,277
Gross Profit 479,483 116,472 587,310 370,300
Operating expenses:        
Sales and marketing 1,531,382 1,133,454 4,291,282 5,925,905
Research and development 768,542 921,706 2,677,310 4,304,317
General and administrative 2,071,443 1,216,043 3,913,047 4,381,067
Total operating expenses 4,371,367 3,271,203 10,881,639 14,611,289
Loss from operations (3,891,884) (3,154,731) (10,294,329) (14,240,989)
Other income (expense):        
Interest expense (426,603) (639,113) (1,726,455) (736,346)
Loss on increase in fair value of warrant liability (77,436,700)       
Interest income 1,400 1,264 5,225 10,692
Non-cash gain on changes in fair value of warrants     186,075 17,126
Other expense, net (11,572) (4,174) (57,890) (92,441)
Total other income (expense), net (77,873,475) (642,023) (1,593,045) (800,969)
Net loss $ (81,765,359) $ (3,796,754) $ (11,887,374) $ (15,041,958)
Basic and diluted net loss per share $ (1.22) $ (0.18)    
Weighted-average number of shares used in computing basic and diluted net loss per share amounts 67,072,057 20,636,529